Skip to content

Functional Microarray Augmentation of Skin Treatment With Lidocaine

Functional Microarray Augmentation of Skin Treatment With Lidocaine (FAST Lidocaine)

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01145326
Acronym
FAST
Enrollment
0
Registered
2010-06-16
Start date
2015-01-31
Completion date
2017-12-31
Last updated
2017-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Perception, Phlebotomy

Keywords

venipuncture, phlebotomy, pain perception

Brief summary

The purpose of this study is to determine whether co-application of a functional microarray of needles (FMA) speeds the rate at which topical anesthesia is provided. A secondary goal is to determine whether the depth of anesthesia is enhanced.

Detailed description

The study's primary goal is to determine whether co-application of a functional microarray of needles (FMA) speeds the rate at which topical anesthesia is provided by lidocaine gel 4% (LG4). A secondary goal is to determine whether the depth of anesthesia is enhanced.

Interventions

DRUG4% lidocaine gel application with sham microneedle device

Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).

Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device

Sponsors

University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

age at least 18 years, must provide voluntary consent, weight at least 50 kg, no allergies to lidocaine, no skin disease, inflammation, or infection at the venipuncture sites to be tested

Exclusion criteria

cannot have any major dermatologic disease history, known liver abnormalities, women who are currently breastfeeding

Design outcomes

Primary

MeasureTime frame
Venipuncture pain levels1 hour

Secondary

MeasureTime frame
Undesirable side effects1 day

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026